Which Agent Best for Neuromyelitis Optica?

A new indirect comparison of three new FDA-approved treatment options for aquaporin4+ neuromyelitis optica has suggested that eculizumab is the most effective. But many limitations have been raised.

Related Keywords

Minnesota ,United States ,Arizona ,Mayo Clinic In Rochester ,Oregon ,Brian Weinshenker ,Dennis Bourdette ,Bruce Cree ,Genentech ,Department Of Neurology ,Oregon Health Science University ,Research In Multiple Sclerosis ,University Of California San Francisco ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Dean Wingerchuk ,Mayo Clinic ,Medscape Medical News ,California San Francisco ,Oregon Health ,Science University ,Multiple Sclerosis Journalthat ,Multiple Sclerosis Ms ,Us ,Multiple Sclerosis Prognosis ,S Prognosis ,Ultiple Sclerosis Prognostic Factors ,S Prognostic Factors ,Primary Progressive Multiple Sclerosis ,Pms ,Immunosuppressive Therapy ,Immunosuppressive Agents ,Immunosuppressive Drugs ,Rug Immunosuppressive ,Relapsing Remitting Multiple Sclerosis ,Arms ,Ultiple Sclerosis Relapsing Remitting ,Multiple Scl ,